This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Cancer; other and unspecified primary
  • /
  • Management of venous thromboembolism (VTE) in canc...

Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines

Read time: 1 mins
Last updated:31st Aug 2011

ESMO guideline for management of venous thromboembolism (VTE) in cancer patients covers clinical risk factors, diagnosis in occult malignancy, prevention of VTE, acute and long-term treatment in solid tumours, and anticoagulant therapy in patients with recurrent VTE.
Venous thromboembolism (VTE) represents one of the most important causes of morbidity and mortality in cancer patients. According to population-based case–control studies, the 2-year cumulative incidence of VTE is between 0.8 and 8% [1]. Patients with the highest 1-year incidence rate of VTE are those with advanced disease of the brain, lung, uterus, bladder, pancreas, stomach and kidney. For these histotypes, the rate of VTE is 4–13 times higher among patients with metastatic disease as compared with those with localized disease.


Read full guideline